Cerebrolysin and Neurodevelopment in Preterm Infants

Overview

The overall aim of the study is to assess the effect of Cerebrolysin on physical and mental development of preterm infants by Denver Scale II at different ages of 5, 7 and 12 months

Full Title of Study: “Efficacy and Safety of Cerebrolysin on Neurodevelopmental Outcome of Preterm Infants”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: June 2019

Detailed Description

There is an inverse relationship between birth weight or gestational age and risk for developmental impairment, with increasing incidence as birth weight or gestational age decreases. Serious impairment, defined as problems in body function or structure which may be temporary or permanent, is generally a more stable condition and typically leads to a disability requiring rehabilitation. Mild impairment is a more reversible condition amenable to early intervention. Studies that have followed extremely preterm and extremely low birth weight infants into school age and early adulthood have shown higher rates of motor, cognitive or behavioral impairments as compared with infants born at term. The neurologic consequences of extreme prematurity range from mild behavioral and cognitive defects to severe disability. Perinatal neuroprotection aims to reduce these outcomes. Cerebrolysin is a porcine brain-derived peptide preparation that acts like endogenous neurotrophic factors. It is produced by a standardized enzymatic breakdown of lipid-free brain protein powder and consists of low molecular weight peptides and free amino acids. The pharmacodynamic effects of Cerebrolysin can be categorized in terms of neuronal survival (e.g. trophic and survival promoting actions), neuroprotection (e.g. limiting neuronal dysfunction, especially in adverse conditions), neuroplasticity (e.g. adaptive responses to changing conditions) and neurogenesis (e.g. promoting differentiation of progenitor cells). We aim to assess the effect of Cerebrolysin on physical and mental development of preterm infants at different ages of life at 5, 7 and 12 months.

Interventions

  • Drug: Cerebrolysin
    • Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).

Arms, Groups and Cohorts

  • Active Comparator: Cerbrolysin
    • Preterm infants with gestational age less than 32 weeks at birth will receive once weekly Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections) starting at the corrected postnatal age of 5 months.
  • No Intervention: Control
    • Preterm infants with gestational age less than 32 weeks at birth will receive routine care.

Clinical Trial Outcome Measures

Primary Measures

  • Neurodevelopmental outcome
    • Time Frame: 9 months
    • Assessment of the physical and mental functions of preterm infant by Denver Developmental Screening Test II (DDST II)

Secondary Measures

  • Side effects of cerebrolysin therapy
    • Time Frame: 9 months
    • Sweating, dizziness, increased heart rate and arrhythmia, loss of appetite, diarrhea, constipation, nausea, irritability, insomnia, and allergic reactions.

Participating in This Clinical Trial

Inclusion Criteria

  • High risk preterm infants born with gestational age less than 32 weeks and have a corrected postnatal age of 5 months at time of enrollment. Included preterm infants should have one or more of the following risk factors which may affect their neurodevelopmental outcome. 1. Infants diagnosed with bronchopulmonary dysplasia requiring oxygen therapy more than 30% FIO2 at 36 weeks corrected gestational age. 2. Infants with culture proven early or late onset neonatal sepsis with or without neonatal meningitis. 3. Infants diagnosed to have peri- ventricular leukomalacia diagnosed by brain imaging. Exclusion Criteria:

1. Patient with persistent uncontrolled fits (all possible reasons for these uncontrolled seizures, including non-epileptic seizures, pseudo intractability, and medically refractory epilepsy. 2. Patient with brain malformation.

Gender Eligibility: All

Minimum Age: 5 Months

Maximum Age: 1 Year

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mansoura University Children Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nehad Nasef, Professor of Pediatrics – Mansoura University Children Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.